CN102286001A - Method for preparing ceftezole sodium - Google Patents
Method for preparing ceftezole sodium Download PDFInfo
- Publication number
- CN102286001A CN102286001A CN2011102526732A CN201110252673A CN102286001A CN 102286001 A CN102286001 A CN 102286001A CN 2011102526732 A CN2011102526732 A CN 2011102526732A CN 201110252673 A CN201110252673 A CN 201110252673A CN 102286001 A CN102286001 A CN 102286001A
- Authority
- CN
- China
- Prior art keywords
- acid
- thiadiazole
- tetrazolium
- ceftezole
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004366 ceftezole Drugs 0.000 title claims abstract description 38
- DZMVCVMFETWNIU-LDYMZIIASA-N ceftezole Chemical compound O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NN=CS1 DZMVCVMFETWNIU-LDYMZIIASA-N 0.000 title claims description 18
- 238000000034 method Methods 0.000 title abstract description 18
- 239000002253 acid Substances 0.000 claims abstract description 17
- JLAMDELLBBZOOX-UHFFFAOYSA-N 3h-1,3,4-thiadiazole-2-thione Chemical compound SC1=NN=CS1 JLAMDELLBBZOOX-UHFFFAOYSA-N 0.000 claims abstract description 15
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 claims abstract description 14
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims abstract description 12
- SKBJRTUEBZMNBA-UHFFFAOYSA-N 1h-tetrazol-1-ium;acetate Chemical compound CC(O)=O.C=1N=NNN=1 SKBJRTUEBZMNBA-UHFFFAOYSA-N 0.000 claims abstract description 11
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims abstract description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003444 phase transfer catalyst Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 238000000746 purification Methods 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 238000003786 synthesis reaction Methods 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- -1 hexadecane triethylammonium chloride Chemical compound 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical group 0.000 claims description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- UGUMHWUOXWFPFH-JHQAJZDGSA-M Ceftezole Sodium Chemical compound [Na+].O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)[O-])=C2CSC1=NN=CS1 UGUMHWUOXWFPFH-JHQAJZDGSA-M 0.000 abstract description 22
- 238000009776 industrial production Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 150000002148 esters Chemical class 0.000 abstract 2
- 238000006555 catalytic reaction Methods 0.000 abstract 1
- 125000001453 quaternary ammonium group Chemical group 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 7
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- YHMYGUUIMTVXNW-UHFFFAOYSA-N 1,3-dihydrobenzimidazole-2-thione Chemical compound C1=CC=C2NC(S)=NC2=C1 YHMYGUUIMTVXNW-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- JUNAPQMUUHSYOV-UHFFFAOYSA-N 2-(2h-tetrazol-5-yl)acetic acid Chemical compound OC(=O)CC=1N=NNN=1 JUNAPQMUUHSYOV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RCTOVWPTGOZSPJ-UHFFFAOYSA-N benzyl(ethyl)azanium;chloride Chemical compound Cl.CCNCC1=CC=CC=C1 RCTOVWPTGOZSPJ-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ICKLSPKTPKWFAP-UHFFFAOYSA-N diazanium;bromide;chloride Chemical compound [NH4+].[NH4+].[Cl-].[Br-] ICKLSPKTPKWFAP-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- WPPGURUIRLDHAB-UHFFFAOYSA-M triethyl(hexadecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](CC)(CC)CC WPPGURUIRLDHAB-UHFFFAOYSA-M 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Cephalosporin Compounds (AREA)
Abstract
本发明公开了一种头孢替唑钠的制备方法,属于药物化学领域。该方法以1H-四氮唑乙酸、2-巯基-1,3,4-噻二唑为原料,在对甲苯磺酸或者二环己基碳二亚胺催化下生成1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯(活性酯),然后将活性酯与7-氨基头孢烷酸在季铵盐相转移催化剂作用下“一锅煮”合成头孢替唑酸,再将其生成钠盐,进一步重结晶纯化得到高纯度的头孢替唑钠。本制备工艺简单易行,原子利用率高,产品质量好,满足工业化生产需求。The invention discloses a preparation method of ceftezole sodium, which belongs to the field of medicinal chemistry. The method uses 1H-tetrazolium acetic acid and 2-mercapto-1,3,4-thiadiazole as raw materials to generate 1H-tetrazolium acetic acid-1 under the catalysis of p-toluenesulfonic acid or dicyclohexylcarbodiimide , 3,4-thiadiazole-2-thioester (active ester), and then the active ester and 7-aminocephalosporanic acid under the action of a quaternary ammonium phase transfer catalyst to synthesize ceftezoleic acid, and then Generate sodium salt, further recrystallization and purification to obtain high-purity ceftezole sodium. The preparation process is simple and easy, the atom utilization rate is high, the product quality is good, and the demand for industrial production can be met.
Description
技术领域 technical field
本发明属于属于药物化学领域,涉及头孢替唑钠药物的合成方法。 The invention belongs to the field of medicinal chemistry and relates to a synthesis method of ceftezole sodium medicine.
背景技术 Background technique
头孢替唑钠,英文名称Ceftezole Sodium,分子量为461.9963,分子式为C13H11N8NaO4S3,化学名称为(6R,7R)-3-{[(1,3,4-噻二唑-2-基)硫]甲基}-7-[(1H-四氮唑-1-基) 乙酰氨基]-8-氧代-5-硫杂-1-氮杂双环[4,2,0]辛-2-烯-2-甲酸钠盐。其结构式如下: Ceftezole sodium, the English name is Ceftezole Sodium, the molecular weight is 461.9963, the molecular formula is C 13 H 11 N 8 NaO 4 S 3 , the chemical name is (6R,7R)-3-{[(1,3,4-thiadiazole -2-yl)thio]methyl}-7-[(1H-tetrazol-1-yl)acetamido]-8-oxo-5-thia-1-azabicyclo[4,2,0 ] Oct-2-ene-2-carboxylic acid sodium salt. Its structural formula is as follows:
头孢替唑钠为第一代注射用半合成头孢菌素类抗生素,作用机制是通过抑制细菌细胞壁的合成而起到抗菌活性。对革兰氏阳性菌尤其是金黄色葡萄球菌、化脓性链球菌、肺炎球菌、溶血性链球菌、草绿色链球菌、表皮葡萄球菌以及白喉杆菌、炭疽杆菌皆比较敏感。对某些革兰氏阴性菌如嗜血杆菌、大肠杆菌、克雷伯杆菌、奇异变形杆菌等作用比较优良,对志贺菌属、沙门菌属、枸橼酸杆菌、部分吲哚阳性变形杆菌也有抗菌作用。临床上主要用于敏感菌所致的感染如肺炎、支气管炎、败血症、腹膜炎、尿路感染及其手术后或外伤引起的感染。 Ceftezole sodium is the first generation of semi-synthetic cephalosporin antibiotics for injection. The mechanism of action is to inhibit the synthesis of bacterial cell walls to achieve antibacterial activity. It is sensitive to Gram-positive bacteria, especially Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumococcus, Streptococcus viridans, Staphylococcus epidermidis, Bacillus diphtheriae and Bacillus anthracis. It has good effect on some Gram-negative bacteria such as Haemophilus, Escherichia coli, Klebsiella, Proteus mirabilis, etc., and has good effect on Shigella, Salmonella, Citrobacter, and some indole-positive Proteus Also has antibacterial effect. Clinically, it is mainly used for infections caused by sensitive bacteria such as pneumonia, bronchitis, sepsis, peritonitis, urinary tract infection and infections caused by post-operative or trauma.
头孢替唑钠是由日本藤泽公司开发,1978年以商品名“Falomesin”上市。1995年进入中国市场,临床用量日益增大,改进其合成工艺线,降低生产成本,将有利于工业生产。 Ceftezole Sodium was developed by Japan Fujisawa Co., Ltd., and was listed under the trade name "Falomesin" in 1978. It entered the Chinese market in 1995, and its clinical usage is increasing day by day. Improving its synthetic process line and reducing production costs will be beneficial to industrial production.
《新编药物合成手册》( 由化学工业出版社、2003年8月出版 )中报道了一种头孢替唑钠的合成方法,以7-ACA为起始原料,与1H-四氮唑乙酸在二环己基碳二亚胺(DCC)作用下反应生成7-位氨基酰化物,再与2-巯基-1,3,4-噻二唑反应生产头孢替唑酸,该方法比较简单,但总收率较低,仅有18.3%。 A kind of synthetic method of ceftezole sodium has been reported in "New Drug Synthesis Handbook" (published by Chemical Industry Press, August, 2003), with 7-ACA as starting material, and 1H-tetrazolium acetic acid in The reaction under the effect of dicyclohexylcarbodiimide (DCC) generates 7-amino acylate, and then reacts with 2-mercapto-1,3,4-thiadiazole to produce ceftezole acid. This method is relatively simple, but always The yield is low, only 18.3%.
专利申请CN101229129A公开了一种上述类似的方法,但是要求原料1H-四氮唑乙酸与DCC和7-ACA的比为1.4~1.7:1~1.3:1,原料用量较大,以二甲亚砜、乙酸乙酯、三乙胺为溶剂,酰化收率只有72.8%,总收率有所提高,为55.0%。 Patent application CN101229129A discloses a method similar to the above, but requires the ratio of raw material 1H-tetrazolium acetic acid to DCC and 7-ACA to be 1.4-1.7:1-1.3:1, and the amount of raw materials is relatively large. , ethyl acetate, and triethylamine are solvents, and the acylation yield is only 72.8%, and the total yield improves to some extent, and is 55.0%.
专利申请CN1803803A公开了一种制备头孢替唑3-位中间体的方法,用7-ACA与2-巯基-1,3,4-噻二唑在一种溶媒络合物中进行反应,所述溶媒络合物为乙腈、甲酸等同三氟化硼的络合物。该方法使用了价格昂贵且高污染的三氟化硼,提高了生产成本,增加了三废处理的难度。 Patent application CN1803803A discloses a method for preparing the 3-position intermediate of ceftezole, reacting in a solvent complex with 7-ACA and 2-mercapto-1,3,4-thiadiazole, the The solvent complex is a complex of acetonitrile, formic acid and boron trifluoride. The method uses expensive and highly polluting boron trifluoride, which raises the production cost and increases the difficulty of treating the three wastes.
专利申请JP 56053684A公开了以7-ACA的氨基酰化物为原料,先与2-巯基苯并咪唑生成硫醚,然后同2-巯基-1,3,4-噻二唑进行硫醚烃基的取代反应生成头孢替唑。该方法引入了与2-巯基苯并咪唑生成硫醚的反应,增加了反应步骤,提高了生产成本。 Patent application JP 56053684A discloses that the amino acylate of 7-ACA is used as a raw material to generate thioether with 2-mercaptobenzimidazole, and then replace the thioether hydrocarbon group with 2-mercapto-1,3,4-thiadiazole The reaction produces ceftezole. The method introduces the reaction of generating thioether with 2-mercaptobenzimidazole, which increases the reaction steps and increases the production cost.
专利申请CN101544659A公开了一种制备头孢替唑的方法,以硼酸为催化剂,用7-ACA与2-巯基-1,3,4-噻二唑在水中进行反应,较高收率地得到了3-位的中间体,但是应用了大量的2-巯基-1,3,4-噻二唑和硼酸,然后与1H-四氮唑乙酰氯反应制备头孢替唑酸,酰化收率低,总收率为38%。 Patent application CN101544659A discloses a method for preparing ceftezole, using boric acid as a catalyst, and reacting 7-ACA with 2-mercapto-1,3,4-thiadiazole in water to obtain 3 - position intermediate, but a large amount of 2-mercapto-1,3,4-thiadiazole and boric acid are used, and then reacted with 1H-tetrazolium acetyl chloride to prepare ceftezole acid, the acylation yield is low, and the total The yield was 38%.
专利申请CN101735250A公开了一种制备头孢替唑钠的方法,即四氮唑乙酸与2-巯基-1,3,4-噻二唑缩合生成四氮唑乙酸-1,3,4-噻二唑-2-硫酯,与7-氨基头孢烷酸反应生成头孢替唑钠,该方法在合成四氮唑乙酸-1,3,4-噻二唑-2-硫酯使用了价格昂贵的试剂氯甲酸异丙酯和N-甲基哌啶,在7-氨基头孢烷酸反应生成头孢替唑钠的反应中使用了氮气,增加了生产成本。 Patent application CN101735250A discloses a method for preparing ceftezole sodium, that is, tetrazoleacetic acid and 2-mercapto-1,3,4-thiadiazole are condensed to form tetrazoleacetic acid-1,3,4-thiadiazole -2-thioester reacts with 7-aminocephalosporanic acid to generate ceftezole sodium, which uses expensive reagent chlorine in the synthesis of tetrazoleacetic acid-1,3,4-thiadiazole-2-thioester Isopropyl formate and N-methylpiperidine used nitrogen in the reaction of 7-aminocephalosporanic acid to generate ceftezole sodium, which increased production costs.
现有技术中合成头孢替唑钠的方法,普遍存在收率低,产物色级差及工业生产成本高等缺点。工艺的难度造成了医院制剂价格的昂贵,给用药者造成了经济负担,且合成过程中使用了污染性强的化学试剂,对环境破坏较大。目前急需对其合成工艺进行改进,满足工业化生产需求。 The method for synthesizing ceftezole sodium in the prior art generally has the disadvantages of low yield, poor product color grade and high industrial production cost. The difficulty of the process has resulted in the high price of the hospital preparations, causing economic burdens to the drug users, and the use of highly polluting chemical reagents in the synthesis process has caused great damage to the environment. At present, it is urgent to improve its synthesis process to meet the needs of industrial production.
发明内容 Contents of the invention
本发明的目的是提供一种简单易行,绿色环保、收率较高、能满足工业化生产需求的头孢替唑钠的合成方法。 The purpose of the present invention is to provide a kind of simple and easy, environmental protection, high yield, the synthetic method of ceftezole sodium that can meet the demand of industrialized production.
为实现上述目的,本发明技术方案如下: To achieve the above object, the technical scheme of the present invention is as follows:
头孢替唑钠的结构式如(Ⅰ)所示: The structural formula of ceftezole sodium is shown in (I):
其合成路线为: Its synthetic route is:
具体步骤如下:(1)1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯(Ⅳ)的合成:将1H-四氮唑乙酸(Ⅱ)和2-巯基-1,3,4-噻二唑(Ⅲ)溶于有机溶剂中,在0℃~4℃的温度下加入催化剂对甲基苯磺酸或者二环己基碳二亚胺,反应结束后过滤即得1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯(Ⅳ);所用有机溶剂为乙酸乙酯、丙酮、四氢呋喃中的一种或几种混合;1H-四氮唑乙酸、2-巯基-1,3,4-噻二唑与对甲基苯磺酸的摩尔比例为1.05~1.10:1.00:0.1。1H-四氮唑乙酸、2-巯基-1,3,4-噻二唑与二环己基碳二亚胺的摩尔比例为1.05~1.10:1.00:1.10。 The specific steps are as follows: (1) Synthesis of 1H-tetrazolium acetic acid-1,3,4-thiadiazole-2-thioester (IV): 1H-tetrazolium acetic acid (II) and 2-mercapto-1 , 3,4-thiadiazole (Ⅲ) is dissolved in an organic solvent, and the catalyst p-toluenesulfonic acid or dicyclohexylcarbodiimide is added at a temperature of 0°C to 4°C, and after the reaction is completed, filter to obtain 1H -tetrazolium acetic acid-1,3,4-thiadiazole-2-thioester (Ⅳ); the organic solvent used is one or more mixtures of ethyl acetate, acetone, tetrahydrofuran; 1H-tetrazolium acetic acid , The molar ratio of 2-mercapto-1,3,4-thiadiazole to p-toluenesulfonic acid is 1.05~1.10:1.00:0.1. 1H-tetrazolium acetic acid, 2-mercapto-1,3,4- The molar ratio of thiadiazole to dicyclohexylcarbodiimide is 1.05-1.10:1.00:1.10.
(2)头孢替唑酸(Ⅴ)的合成:将7-氨基头孢烷酸和醋酸钠或者碳酸氢钠加入水和乙醇的混合溶剂中,在0℃至5℃下加入步骤(1)所制得的1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯(Ⅳ),而后温度升至30℃进行反应,再加相转移催化剂和有机溶剂,温度升至58℃至62℃反应;HPLC监测反应完成,过滤,滤液用酸调节pH至2.0~3.0,过滤即得头孢替唑酸;相转移催化剂为季铵盐三乙基苄基氯化铵、四丁基溴化铵、十六烷基三乙基氯化铵、四甲基氯化铵或二茂铁季铵盐;所用有机溶剂为乙酸乙酯、甲苯、环己烷中的一种或几种;7-氨基头孢烷酸、1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯(Ⅳ)、与相转移催化剂的摩尔比例为1.00:1.05~1.10:0.15;混合溶剂中水和乙醇体积比1:1; (2) Synthesis of ceftezoleic acid (Ⅴ): Add 7-aminocephalosporanic acid and sodium acetate or sodium bicarbonate into a mixed solvent of water and ethanol, and add the prepared product in step (1) at 0°C to 5°C The obtained 1H-tetrazolium acetic acid-1,3,4-thiadiazole-2-thioester (Ⅳ), then the temperature is raised to 30°C for reaction, and then a phase transfer catalyst and an organic solvent are added, and the temperature is raised to 58°C React at 62°C; monitor the completion of the reaction by HPLC, filter, adjust the pH of the filtrate to 2.0-3.0 with acid, and filter to obtain ceftezole acid; the phase transfer catalyst is quaternary ammonium salt triethylbenzyl ammonium chloride, tetrabutyl bromide ammonium chloride, cetyltriethylammonium chloride, tetramethylammonium chloride or ferrocene quaternary ammonium salt; the organic solvent used is one or more of ethyl acetate, toluene, cyclohexane; 7 -Aminocephalosporanic acid, 1H-tetrazolium acetic acid-1,3,4-thiadiazole-2-thioester (Ⅳ), and the molar ratio of the phase transfer catalyst is 1.00:1.05~1.10:0.15; in the mixed solvent The volume ratio of water and ethanol is 1:1;
(3)头孢替唑钠(Ⅰ)的合成及纯化:将步骤(2)所得的头孢替唑酸粗品加入到含等摩尔量的碳酸氢钠水溶液和异丙醇中,蒸去溶剂,搅拌析晶,即得头孢替唑钠。 (3) Synthesis and purification of ceftezole sodium (I): add the crude product of ceftezole acid obtained in step (2) into an aqueous solution of sodium bicarbonate and isopropanol containing equimolar amounts, evaporate the solvent, stir and analyze crystals to obtain ceftezole sodium.
所述溶剂水的质量等于头孢替唑酸的质量,且水与异丙醇的体积比为1:2,析晶温度为0℃~4℃。 The mass of the solvent water is equal to the mass of ceftezole acid, and the volume ratio of water to isopropanol is 1:2, and the crystallization temperature is 0°C to 4°C.
与现有工艺相比,本发明优点:优选了反应物配比,减少了副反应的发生,提高了产品收率。采用“一锅煮”的方法,简化操作步骤,工艺的原子经济性高,有机溶剂可回收利用,减少了环境污染,绿色环保、工艺简单易行,产品的质量高,降低了生产成本,能满足工业化生产需求。 Compared with the existing technology, the present invention has the advantages of optimizing the ratio of reactants, reducing the occurrence of side reactions and increasing the product yield. The "one pot cooking" method is adopted to simplify the operation steps, the process has high atomic economy, the organic solvent can be recycled, and the environmental pollution is reduced. It is green and environmentally friendly, the process is simple and easy, the quality of the product is high, the production cost is reduced, and it can meet the needs of industrialization. production needs.
具体实施方式 Detailed ways
以下通过实施例来进一步解释或说明本发明的内容,但所提供的实施例不应被理解为对本发明的保护范围构成限制。 The content of the present invention is further explained or illustrated by the following examples, but the provided examples should not be construed as limiting the protection scope of the present invention.
实施例1 Example 1
1、1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯的合成 1. Synthesis of 1H-tetrazolium acetic acid-1,3,4-thiadiazole-2-thioester
将1H-四氮唑乙酸134.4g(1.05mol)和2-巯基-1,3,4-噻二唑118.0g(1.00mol)溶于1000mL四氢呋喃中,降温至0℃~4℃,然后再加入对甲基苯磺酸17.2g(0.10mol)的四氢呋喃溶液50mL,保持温度反应2h,减压蒸馏回收溶剂,降温至0℃~4℃,过滤,得到220.8g的1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯,收率96.8%。 Dissolve 134.4g (1.05mol) of 1H-tetrazoliumacetic acid and 118.0g (1.00mol) of 2-mercapto-1,3,4-thiadiazole in 1000mL tetrahydrofuran, cool down to 0°C to 4°C, and then add 17.2g (0.10mol) of p-toluenesulfonic acid in tetrahydrofuran (50mL) was kept at the temperature for 2 hours, the solvent was recovered by distillation under reduced pressure, the temperature was lowered to 0°C to 4°C, and 220.8g of 1H-tetrazoliumacetic acid-1 was obtained by filtration. , 3,4-thiadiazole-2-thioester, the yield was 96.8%.
2、头孢替唑酸的合成 2, the synthesis of ceftezole acid
将7-氨基头孢烷酸(7-ACA )227.0g(0.83mol)和结晶乙酸钠112.9g(0.83mol)加入1500mL水和1500mL乙醇中,搅拌使溶解,冰浴降温至0℃~4℃,然后以1.0:1.2摩尔比加入上述制备好的1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯,搅拌反应0.5h,然后升温至30℃搅拌2h,再加入三乙基苄基氯化铵(TEBA)28.4g(0.12mol)和300mL乙酸乙酯进一步升温至58℃至62℃,反应5h,减压蒸出回收有机溶剂,冷却至室温,滤液用5%的盐酸调节pH2.0,在0℃~4℃搅拌析晶2h,过滤即得头孢替唑酸326.7g,收率89.4%。 Add 227.0g (0.83mol) of 7-aminocephalosporanic acid (7-ACA) and 112.9g (0.83mol) of crystalline sodium acetate into 1500mL of water and 1500mL of ethanol, stir to dissolve, cool down to 0°C to 4°C in an ice bath, Then add the above-prepared 1H-tetrazolium acetic acid-1,3,4-thiadiazole-2-thioester at a molar ratio of 1.0:1.2, stir for 0.5h, then raise the temperature to 30°C and stir for 2h, then add three Ethylbenzyl ammonium chloride (TEBA) 28.4g (0.12mol) and 300mL ethyl acetate were further heated to 58°C to 62°C, reacted for 5h, evaporated under reduced pressure to recover the organic solvent, cooled to room temperature, and the filtrate was washed with 5% Adjust the pH to 2.0 with hydrochloric acid, stir and crystallize at 0°C to 4°C for 2h, and filter to obtain 326.7g of ceftezole acid, with a yield of 89.4%.
3、头孢替唑钠的合成及精制 3. Synthesis and refining of ceftezole sodium
将头孢替唑酸150.0g加入含等摩尔量的碳酸氢钠水溶液150mL中,再加入异丙醇300mL,搅拌析出杂质,过滤,蒸去溶剂,在0℃~4℃下搅拌析晶,过滤,用冰乙醇50mL洗涤,40℃下减压干燥,得头孢替唑钠137.9g,收率87.6%。 Add 150.0 g of ceftezoleic acid into 150 mL of an aqueous sodium bicarbonate solution containing an equimolar amount, then add 300 mL of isopropanol, stir to precipitate impurities, filter, evaporate the solvent, stir and crystallize at 0°C to 4°C, and filter. Wash with 50 mL of ice ethanol, and dry under reduced pressure at 40°C to obtain 137.9 g of ceftezole sodium, with a yield of 87.6%.
实施例2 Example 2
1、1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯的合成 1. Synthesis of 1H-tetrazolium acetic acid-1,3,4-thiadiazole-2-thioester
将1H-四氮唑乙酸134.4g(1.05mol)和2-巯基-1,3,4-噻二唑118.0g(1.00mol)溶于1200mL乙酸乙酯中,降温至0℃~4℃,然后再加入226.6g(1.10mol) 二环己基碳二亚胺(DCC)和乙酸乙酯溶液500mL,保持温度反应2h,减压蒸馏回收溶剂,降温至0℃~4℃,过滤,得到213.8g的1H-四氮唑乙酸-1,3,4-噻二唑-2-硫酯,收率93.7%。 Dissolve 134.4 g (1.05 mol) of 1H-tetrazolium acetic acid and 118.0 g (1.00 mol) of 2-mercapto-1,3,4-thiadiazole in 1200 mL of ethyl acetate, lower the temperature to 0°C to 4°C, and then Then add 226.6g (1.10mol) of dicyclohexylcarbodiimide (DCC) and 500mL of ethyl acetate solution, keep the temperature for reaction for 2h, recover the solvent by distillation under reduced pressure, cool down to 0℃~4℃, and filter to obtain 213.8g of 1H-tetrazolium acetic acid-1,3,4-thiadiazole-2-thioester, yield 93.7%.
2、头孢替唑酸的合成 2. Synthesis of Ceftezole Acid
同实施例1,相转移催化剂采用四丁基溴化铵;所用有机溶剂为甲苯。 Same as Example 1, the phase transfer catalyst adopts tetrabutylammonium bromide; the organic solvent used is toluene.
3、头孢替唑钠的合成及精制 3. Synthesis and refining of ceftezole sodium
同实施例1。得头孢替唑钠135.6g,收率86.1 %。 With embodiment 1. Get Ceftezole Sodium 135.6g, yield 86.1%.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102526732A CN102286001A (en) | 2011-08-30 | 2011-08-30 | Method for preparing ceftezole sodium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102526732A CN102286001A (en) | 2011-08-30 | 2011-08-30 | Method for preparing ceftezole sodium |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102286001A true CN102286001A (en) | 2011-12-21 |
Family
ID=45332777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011102526732A Pending CN102286001A (en) | 2011-08-30 | 2011-08-30 | Method for preparing ceftezole sodium |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102286001A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103183687A (en) * | 2011-12-30 | 2013-07-03 | 山东天绿制药有限公司 | Phase transfer catalysis method for preparing cefdinir |
CN105030787A (en) * | 2015-09-15 | 2015-11-11 | 青岛华之草医药科技有限公司 | Ceftezole sodium composition serving as medicine for treating bacterial infection |
CN105061473A (en) * | 2015-09-15 | 2015-11-18 | 青岛华之草医药科技有限公司 | Sterilization medicine ceftezole sodium compound and preparation method thereof |
CN105085547A (en) * | 2015-03-05 | 2015-11-25 | 石药集团中诺药业(石家庄)有限公司 | Novel ceftezole sodium compound |
CN105131018A (en) * | 2015-09-23 | 2015-12-09 | 浙江华方药业股份有限公司 | Preparation method of ceftezole acid |
CN108129493A (en) * | 2018-02-07 | 2018-06-08 | 宁夏天心医药有限责任公司 | A kind of Cefobutazine sodium compound and its preparation |
CN109160922A (en) * | 2017-07-20 | 2019-01-08 | 海南灵康制药有限公司 | A kind of 1/2 water Cefobutazine sodium compound |
CN109336907A (en) * | 2018-11-21 | 2019-02-15 | 山东罗欣药业集团股份有限公司 | A kind of preparation method of cefobutazine sodium |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0004570A1 (en) * | 1978-03-09 | 1979-10-17 | Asahi Kasei Kogyo Kabushiki Kaisha | Thiol esters, process for their preparation, pharmaceutical compositions containing them and a process for preparing cephalosporin compounds using the same |
US4327211A (en) * | 1980-11-26 | 1982-04-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for preparation of cephalosporin compounds |
CN101696215A (en) * | 2009-08-28 | 2010-04-21 | 海南美大制药有限公司 | Cefazolin sodium pentahydrate compound of new route |
CN101735250A (en) * | 2009-12-02 | 2010-06-16 | 王明 | Ceftezole sodium compound with novel route |
-
2011
- 2011-08-30 CN CN2011102526732A patent/CN102286001A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0004570A1 (en) * | 1978-03-09 | 1979-10-17 | Asahi Kasei Kogyo Kabushiki Kaisha | Thiol esters, process for their preparation, pharmaceutical compositions containing them and a process for preparing cephalosporin compounds using the same |
US4327211A (en) * | 1980-11-26 | 1982-04-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for preparation of cephalosporin compounds |
CN101696215A (en) * | 2009-08-28 | 2010-04-21 | 海南美大制药有限公司 | Cefazolin sodium pentahydrate compound of new route |
CN101735250A (en) * | 2009-12-02 | 2010-06-16 | 王明 | Ceftezole sodium compound with novel route |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103183687A (en) * | 2011-12-30 | 2013-07-03 | 山东天绿制药有限公司 | Phase transfer catalysis method for preparing cefdinir |
CN105085547A (en) * | 2015-03-05 | 2015-11-25 | 石药集团中诺药业(石家庄)有限公司 | Novel ceftezole sodium compound |
CN105030787A (en) * | 2015-09-15 | 2015-11-11 | 青岛华之草医药科技有限公司 | Ceftezole sodium composition serving as medicine for treating bacterial infection |
CN105061473A (en) * | 2015-09-15 | 2015-11-18 | 青岛华之草医药科技有限公司 | Sterilization medicine ceftezole sodium compound and preparation method thereof |
CN105131018A (en) * | 2015-09-23 | 2015-12-09 | 浙江华方药业股份有限公司 | Preparation method of ceftezole acid |
CN109160922A (en) * | 2017-07-20 | 2019-01-08 | 海南灵康制药有限公司 | A kind of 1/2 water Cefobutazine sodium compound |
CN108129493A (en) * | 2018-02-07 | 2018-06-08 | 宁夏天心医药有限责任公司 | A kind of Cefobutazine sodium compound and its preparation |
CN109336907A (en) * | 2018-11-21 | 2019-02-15 | 山东罗欣药业集团股份有限公司 | A kind of preparation method of cefobutazine sodium |
CN109336907B (en) * | 2018-11-21 | 2020-05-26 | 山东罗欣药业集团股份有限公司 | Preparation method of ceftezole sodium |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102286001A (en) | Method for preparing ceftezole sodium | |
CN101613361B (en) | Method for preparing cefoxitin sodium | |
CN102617607B (en) | Method for preparing cefazolin compounds | |
CN101812076B (en) | Cefuroxime sodium and preparation method thereof | |
CN104725425B (en) | A kind of preparation method of Ceftaroline Fosamil | |
US4012382A (en) | α-Amino and α-formyl-α-(p-acyloxyphenyl)acetamidocephalosporanic acid derivatives | |
CN102030762B (en) | Preparation method of cefprozil | |
CN101735250B (en) | Synthesis method of ceftezole sodium compound | |
CN101671349B (en) | New method for preparing cefuroxime sodium compound | |
CN102219794A (en) | Preparation method of ceftizoxime sodium | |
CN104447800B (en) | A kind of synthetic technology of cefoxitin acid | |
CN103030651A (en) | Method for preparing ceftazidime hydrochloride | |
CN101696215B (en) | Cefazolin sodium pentahydrate compound of new route | |
CN101671348B (en) | Ceftizoxime sosium compound of new way | |
CN110407857B (en) | Preparation process of cefathiamidine | |
CN108033971B (en) | Method for synthesizing cefcapene pivoxil hydrochloride | |
CN108084212B (en) | Preparation method of cefditoren pivoxil | |
CN116332955A (en) | Preparation method of cefditoren pivoxil intermediate | |
CN101130803A (en) | A method for enzymatically synthesizing β-lactam antibiotics in organic solvents | |
CN101607965A (en) | A kind of novel process for preparing Wy-44635 | |
CN101550150A (en) | Cefmenoxime compound and synthetic method thereof | |
CN108299469B (en) | Preparation method of cefotiam hydrochloride | |
US20080306256A1 (en) | Salts in the Preparation of Cephalosporin Antibiodies | |
CN114805393A (en) | A kind of preparation method of cefprozil | |
CA2190245A1 (en) | Cephalosporin compounds and processes for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20111221 |